ClinicalTrials.gg
CompletedNCT00731120Updated Dec 18, 2013Results posted

Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

A Phase 3 interventional study of Vortioxetine and Placebo in Generalized Anxiety Disorder, sponsored by Takeda. Completed at 40 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-18.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
457
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 265 studies in Generalized Anxiety Disorder with a site in United States — 38 open to participants now, 53 under way, 9 of them phase 3. Generalized Anxiety Disorder · United States.

Enrollment
29th of 234
457 · median 90
Started
2008
with 19 others
Phase 3
45 of 265
6 open now
Registered
64th of 265
by date

Among the 265 studies in Generalized Anxiety Disorder with a site in United States, this one is the 29th largest by enrollment of the 234 interventional ones that give a count, is one of 20 that started in 2008, is one of 45 in phase 3, and was the 64th registered.

Generalized Anxiety Disorder

518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.

Browse Generalized Anxiety Disorder studies →

Open to participants now

38 of the 265 studies in Generalized Anxiety Disorder with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 52 (60%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Generalized Anxiety Disorder with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of 2.5 mg and 10 mg vortioxetine, once daily (QD), in adults with generalized anxiety disorder.

Read the detailed description

Participants in this study will be randomly assigned to receive either 2.5 mg or 10 mg of vortioxetine or a placebo once daily for an eight week treatment period.

Participants will be seen weekly during the first 2 weeks of treatment, and then every 2 weeks up to the end of the 8-week treatment period. Total commitment time is up to 12 weeks.

03

Conditions studied

  • Generalized Anxiety Disorder

Keywords

  • Generalized Anxiety Disorder
  • Mood Disorder
  • Affective Disorder
  • Anxiety Disorder
  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a primary diagnosis of Generalized Anxiety Disorder according to , 4th Edition, Text Revision (DSM-IV-TR®) criteria (classification code 300.02).
  • Has a Hamilton Anxiety Scale total score ≥ 20.
  • Has a Hamilton Anxiety Scale score ≥ 2 on both item 1 (anxious mood) and item 2 (tension).
  • Has a Montgomery-Åsberg Depression Rating Scale total score ≤16.

Exclusion criteria

Exclusion Criteria:

  • Has 1 or more of the following:

    • Any current psychiatric disorder other than Generalized Anxiety Disorder as defined in the (as assessed by the Mini International Neuropsychiatric Interview [MINI]).
    • Current or past history of: manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR.
    • Any substance disorder (except nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR and participant must have a negative urine drug screen prior to Baseline.
    • Presence or history of a neurological disorder (including epilepsy).
    • Neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease, etc.).
    • Any Axis II disorder that might compromise the study.
  • Is taking excluded medications.
  • Has a significant risk of suicide according to the investigator's opinion or has a score ≥5 on Item 10 (suicidal thoughts) of the Montgomery-Åsberg Depression Rating Scale or has made a suicide attempt in the previous 6 months.
  • Has previously failed to respond to adequate treatment with selective serotonin reuptake inhibitors and/or serotonin-norepinephrine reuptake inhibitors.
  • Has received electroconvulsive therapy within 6 months prior to Screening.
  • Is currently receiving formal cognitive or behavioral therapy, systematic psychotherapy, or plans to initiate such therapy during the study.
  • Has a clinically significant unstable illness.
  • Has an , aspartate aminotransferase, or total level > 1.5 times the .
  • Has a serum creatinine of > 1.5 × the upper limit of normal.
  • Has a previous history of cancer that had been in remission for less than 5 years.
  • Has thyroid stimulating hormone value outside the normal range.
  • Has an abnormal .
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
457 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.

    Drug: Placebo

  • Experimental
    Vortioxetine 2.5 mg

    Vortioxetine 2.5 mg encapsulated tablets, orally, once daily for up to 8 weeks.

    Drug: Vortioxetine

  • Experimental
    Vortioxetine 10 mg

    Vortioxetine 10 mg encapsulated tablets, orally, once daily for up to 8 weeks.

    Drug: Vortioxetine

Interventions

  • Encapsulated vortioxetine immediate-release tablets

    Also known as: Lu AA21004, Brintellix®

  • DrugPlacebo

    Vortioxetine placebo-matching capsules

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score

    The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Least Squares (LS) means were from an analysis of covariance (ANCOVA) model with treatment and center as fixed factors and the Baseline value as a covariate.

    Time frame: Baseline and Week 8

Secondary outcomes

  1. Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed

    The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

    Time frame: Baseline and Weeks 1, 2, 4 and 6

  2. Percentage of Responders in HAM-A Total Score at Week 8

    Response was defined as a participant with a ≥50% decrease from Baseline in the HAM-A total score. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).

    Time frame: Baseline and Week 8

  3. Percentage of Participants in HAM-A Remission at Week 8

    Remission is defined as a Hamilton Anxiety Scale (HAM-A) total score ≤ 7. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).

    Time frame: Week 8

  4. Clinical Global Impression Scale-Global Improvement (CGI-I) at Each Week Assessed

    The Clinical Global Impression - Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from an ANCOVA model adjusting for Baseline CGI-S score, center, and treatment.

    Time frame: Baseline and Weeks 1, 2, 4, 6 and 8.

  5. Change From Baseline in Clinical Global Impression Scale-Severity of Illness (CGI-S)

    The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means were from an ANCOVA model adjusting for Baseline score, center, and treatment.

    Time frame: Baseline and Weeks 1, 2, 4, 6 and 8.

  6. Change From Baseline in Hospital Anxiety and Depression (HAD) Scales

    The HAD scale is completed by the participant and comprises two subscales, one measuring depression (focusing on the state of lost interest and diminished pleasure response) and one measuring anxiety (including anxious mood, restlessness, anxious thoughts, panic attacks). Each subscale is made up of 7 items that are assessed on a scale of 0 = no anxiety/depression to 3 = severe feeling of anxiety/depression. Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. Scores for the depression and anxiety subscales are summed separately and not combined, with each score ranging from 0 to 21 (maximal severity). LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

    Time frame: Baseline and Weeks 1, 4 and 8.

  7. Change From Baseline in Sheehan Disability Scale (SDS) at Week 8

    The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

    Time frame: Baseline and Week 8

  8. Change From Baseline in 36-item Short-form Health Survey (SF-36)

    The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The 8 health concepts are: 1. Limitation in physical activities because of health problems. 2. Limitations in usual role activities because of physical health problems. 3. Bodily pain. 4. Limitations in social activities because of physical or emotional problems. 5. General mental health (psychological distress and well-being). 6. Limitations in usual role activities because of emotional problems. 7. Vitality (energy and fatigue). 8. General health perception. Each scale ranges from 0 (best) - 100 (worst). LS means were from an ANCOVA model with treatment and center as fixed factors and the baseline value as a covariate.

    Time frame: Baseline and Week 8

  9. Health Care Resource Utilization Assessed by the Health Economic Assessment Questionnaire

    Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.

    Time frame: Baseline and Week 8

07

Results

Posted Dec 18, 2013

Participant flow

Participants took part in the study at 41 investigative sites in the United States from 17 June 2008 to 16 February 2009.

Participant flow — Overall Study
MilestonePlaceboVortioxetine 2.5 mgVortioxetine 10 mg
Started153152152
Treated153151152
Completed111109116
Not completed424336
Withdrew: Adverse event768
Withdrew: Lack of efficacy454
Withdrew: Noncompliance with study drug331
Withdrew: Protocol deviations161
Withdrew: Withdrawal of consent1384
Withdrew: Lost to follow-up101517
Withdrew: Other401

Outcome measures

PrimaryChange From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score

The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Least Squares (LS) means were from an analysis of covariance (ANCOVA) model with treatment and center as fixed factors and the Baseline value as a covariate.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score
scores on a scalePlaceboVortioxetine 2.5 mgVortioxetine 10 mg
Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score-9.87 ± 0.584-10.75 ± 0.569-10.68 ± 0.581
Statistical analysis
  • Placebo vs Vortioxetine 2.5 mg · ANCOVA · p = 0.279 (Hierarchical testing stopped at 10 mg versus placebo for HAM-A total score at Week 8 in the testing sequence, a nominal p-value is provided.) · Ls mean difference: -0.87 · 95% CI -2.45 to 0.71Analysis of covariance (ANCOVA), with treatment and center as fixed factors and baseline HAM-A as a covariate.
  • Placebo vs Vortioxetine 10 mg · ANCOVA · p = 0.306 (Pre-specified sequential statistical testing procedure indicates that when p-value \>0.05, hierarchical testing stops and for subsequent endpoints in the sequence a nominal p-value is provided.) · Ls mean difference: -0.81 · 95% CI -2.36 to 0.74Analysis of covariance (ANCOVA), with treatment and center as fixed factors and baseline HAM-A as a covariate.
SecondaryChange From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed

The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56 where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

Time frame:
Baseline and Weeks 1, 2, 4 and 6
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Hamilton Anxiety Scale (HAM-A) Total Score at Other Weeks Assessed
scores on a scalePlaceboVortioxetine 2.5 mgVortioxetine 10 mg
Week 1 (n=147, 142, 143)-5.07 ± 0.433-5.29 ± 0.423-5.30 ± 0.433
Week 2 (n=148, 144, 146)-7.41 ± 0.501-8.11 ± 0.488-8.05 ± 0.499
Week 4 (n=148, 144, 146)-8.88 ± 0.566-9.45 ± 0.551-9.54 ± 0.564
Week 6 (n=148, 144, 146)-9.54 ± 0.565-10.35 ± 0.550-10.50 ± 0.563
SecondaryPercentage of Responders in HAM-A Total Score at Week 8

Response was defined as a participant with a ≥50% decrease from Baseline in the HAM-A total score. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).

Time frame:
Baseline and Week 8
Reported as:
Number · percentage of participants
Percentage of Responders in HAM-A Total Score at Week 8
percentage of participantsPlaceboVortioxetine 2.5 mgVortioxetine 10 mg
Percentage of Responders in HAM-A Total Score at Week 841.946.541.8
SecondaryPercentage of Participants in HAM-A Remission at Week 8

Remission is defined as a Hamilton Anxiety Scale (HAM-A) total score ≤ 7. The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 (symptoms absent) to 56 (maximum severity).

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants in HAM-A Remission at Week 8
percentage of participantsPlaceboVortioxetine 2.5 mgVortioxetine 10 mg
Percentage of Participants in HAM-A Remission at Week 821.621.519.2
SecondaryClinical Global Impression Scale-Global Improvement (CGI-I) at Each Week Assessed

The Clinical Global Impression - Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from an ANCOVA model adjusting for Baseline CGI-S score, center, and treatment.

Time frame:
Baseline and Weeks 1, 2, 4, 6 and 8.
Reported as:
Least squares mean · scores on a scale
Clinical Global Impression Scale-Global Improvement (CGI-I) at Each Week Assessed
scores on a scalePlaceboVortioxetine 2.5 mgVortioxetine 10 mg
Week 1 (n=146, 141, 143)3.35 ± 0.0713.30 ± 0.0703.38 ± 0.071
Week 2 (n=148, 143, 146)2.99 ± 0.0832.91 ± 0.0812.92 ± 0.083
Week 4 (n=148, 144, 146)2.87 ± 0.0892.75 ± 0.0862.69 ± 0.088
Week 6 (n=148, 144, 146)2.68 ± 0.0892.58 ± 0.0872.60 ± 0.088
Week 8 (n=148, 144, 146)2.60 ± 0.0952.56 ± 0.0932.51 ± 0.095
SecondaryChange From Baseline in Clinical Global Impression Scale-Severity of Illness (CGI-S)

The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the participant's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means were from an ANCOVA model adjusting for Baseline score, center, and treatment.

Time frame:
Baseline and Weeks 1, 2, 4, 6 and 8.
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Clinical Global Impression Scale-Severity of Illness (CGI-S)
scores on a scalePlaceboVortioxetine 2.5 mgVortioxetine 10 mg
Week 1 (n=146, 140, 143)-0.40 ± 0.054-0.47 ± 0.053-0.37 ± 0.054
Week 2 (n=148, 143, 146)-0.68 ± 0.072-0.82 ± 0.070-0.69 ± 0.071
Week 4 (n=148, 144, 146)-0.82 ± 0.081-1.01 ± 0.079-0.93 ± 0.081
Week 6 (n=148, 144, 146)-0.93 ± 0.083-1.14 ± 0.081-1.03 ± 0.082
Week 8 (n=148, 144, 146)-1.10 ± 0.090-1.21 ± 0.088-1.14 ± 0.090
SecondaryChange From Baseline in Hospital Anxiety and Depression (HAD) Scales

The HAD scale is completed by the participant and comprises two subscales, one measuring depression (focusing on the state of lost interest and diminished pleasure response) and one measuring anxiety (including anxious mood, restlessness, anxious thoughts, panic attacks). Each subscale is made up of 7 items that are assessed on a scale of 0 = no anxiety/depression to 3 = severe feeling of anxiety/depression. Participants are required to indicate the response which most accurately reflects the way they have felt over the last few days. Scores for the depression and anxiety subscales are summed separately and not combined, with each score ranging from 0 to 21 (maximal severity). LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

Time frame:
Baseline and Weeks 1, 4 and 8.
Reported as:
Mean · scores on a scale
Change From Baseline in Hospital Anxiety and Depression (HAD) Scales
scores on a scalePlaceboVortioxetine 2.5 mgVortioxetine 10 mg
Anxiety Scale at Week 1 (n=147, 142, 143)-1.64 ± 0.266-2.07 ± 0.258-2.03 ± 0.264
Anxiety Scale at Week 4 (n=148, 144, 146)-2.81 ± 0.343-3.66 ± 0.333-3.39 ± 0.339
Anxiety Scale at Week 8 (n=148, 144, 146)-3.63 ± 0.365-4.29 ± 0.354-4.20 ± 0.361
Depression Scale at Week 1 (n=147, 142, 143)-0.71 ± 0.226-1.35 ± 0.220-1.15 ± 0.225
Depression Scale at Week 4 (n=148, 144, 146)-1.66 ± 0.272-2.23 ± 0.265-2.10 ± 0.271
Depression Scale at Week 8 (n=148, 144, 146)-1.76 ± 0.308-2.56 ± 0.300-2.21 ± 0.306
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) at Week 8

The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Sheehan Disability Scale (SDS) at Week 8
scores on a scalePlaceboVortioxetine 2.5 mgVortioxetine 10 mg
Change From Baseline in Sheehan Disability Scale (SDS) at Week 8-4.26 ± 0.617-5.73 ± 0.623-5.24 ± 0.657
SecondaryChange From Baseline in 36-item Short-form Health Survey (SF-36)

The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The 8 health concepts are: 1. Limitation in physical activities because of health problems. 2. Limitations in usual role activities because of physical health problems. 3. Bodily pain. 4. Limitations in social activities because of physical or emotional problems. 5. General mental health (psychological distress and well-being). 6. Limitations in usual role activities because of emotional problems. 7. Vitality (energy and fatigue). 8. General health perception. Each scale ranges from 0 (best) - 100 (worst). LS means were from an ANCOVA model with treatment and center as fixed factors and the baseline value as a covariate.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in 36-item Short-form Health Survey (SF-36)
scores on a scalePlaceboVortioxetine 2.5 mgVortioxetine 10 mg
Physical functioning subscore0.46 ± 1.5132.69 ± 1.4782.07 ± 1.517
Role - physical subscore4.44 ± 2.0188.17 ± 1.9726.17 ± 2.026
Bodily pain subscore5.90 ± 1.90110.67 ± 1.8558.12 ± 1.905
General health subscore4.44 ± 1.2897.01 ± 1.2585.90 ± 1.292
Vitality subscore12.35 ± 1.78215.62 ± 1.74014.33 ± 1.783
Social functioning subscore15.35 ± 2.07518.38 ± 2.02517.56 ± 2.070
Role-emotional subscore15.16 ± 2.07621.72 ± 2.02816.60 ± 2.081
Mental health subscore12.93 ± 1.64217.25 ± 1.60814.74 ± 1.643
SecondaryHealth Care Resource Utilization Assessed by the Health Economic Assessment Questionnaire

Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.

Time frame:
Baseline and Week 8
Reported as:
Number · participants
Health Care Resource Utilization Assessed by the Health Economic Assessment Questionnaire
participantsPlaceboVortioxetine 2.5 mgVortioxetine 10 mg
Baseline: Any resource use323432
Baseline: Any hospitalization-related services211
Baseline: Hospitalization related to anxiety100
Baseline: Any sick leave51310
Baseline: Sick leave related to anxiety484
Week 8: Any resource use142319
Week 8: Any hospitalization-related service301
Week 8: Hospitalization related to anxiety000
Week 8: Any sick leave568
Week 8: Sick leave related to anxiety141

Adverse events

Collected over From the first dose of double-blind study medication through 30 days after permanent discontinuation of double-blind study medication.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/153 (0.7%)70/153 (45.8%)
Vortioxetine 2.5 mg—2/151 (1.3%)72/151 (47.7%)
Vortioxetine 10 mg—1/152 (0.7%)83/152 (54.6%)
Most frequent serious events
Most frequent serious events
EventPlaceboVortioxetine 2.5 mgVortioxetine 10 mg
Inguinal herniaGastrointestinal disorders0/1531/1510/152
PyrexiaGeneral disorders0/1531/1510/152
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/1530/1511/152
Vertigo positionalEar and labyrinth disorders1/1530/1510/152
Most frequent other events
Showing 10 of 19
Most frequent other events
EventPlaceboVortioxetine 2.5 mgVortioxetine 10 mg
NauseaGastrointestinal disorders13/15324/15137/152
HeadacheNervous system disorders17/15320/15118/152
DiarrhoeaGastrointestinal disorders11/15313/15117/152
Dry mouthGastrointestinal disorders17/15314/15112/152
ConstipationGastrointestinal disorders6/1534/1519/152
VomitingGastrointestinal disorders4/1533/1518/152
NasopharyngitisInfections and infestations8/1535/1514/152
DizzinessNervous system disorders6/1537/1516/152
FatigueGeneral disorders2/1533/1517/152
Back painMusculoskeletal and connective tissue disorders2/1536/1513/152

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboVortioxetine 2.5 mgVortioxetine 10 mgTotal
Mean39.5 ± 13.4540.8 ± 13.8143.3 ± 14.9941.2 ± 14.15
Age, Customized
Age, Customized(participants)PlaceboVortioxetine 2.5 mgVortioxetine 10 mgTotal
≤55 years136127120383
>55 years17253274
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboVortioxetine 2.5 mgVortioxetine 10 mgTotal
Female10510396304
Male484956153
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboVortioxetine 2.5 mgVortioxetine 10 mgTotal
Hispanic/Latino13181546
Non-Hispanic/Non-Latino140134137411
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboVortioxetine 2.5 mgVortioxetine 10 mgTotal
Caucasian (White, including Hispanic)105110112327
Black463838122
Asian2327
American Indian or Alaska Native0101
Region of Enrollment
Region of Enrollment(participants)PlaceboVortioxetine 2.5 mgVortioxetine 10 mgTotal
United States153152152457
Weight
Weight(kg)PlaceboVortioxetine 2.5 mgVortioxetine 10 mgTotal
Mean82.66 ± 20.73184.48 ± 22.72785.67 ± 23.24984.27 ± 22.245
Height
Height(cm)PlaceboVortioxetine 2.5 mgVortioxetine 10 mgTotal
Mean168.31 ± 9.994168.63 ± 8.932168.86 ± 10.032168.60 ± 9.649

8 further baseline measures are reported on the registry.

08

Study locations

40 sites
  • Birmingham, Alabama, United States
  • Anaheim, California, United States
  • Cerritos, California, United States
  • Costa Mesa, California, United States
  • Orange, California, United States
  • Redlands, California, United States
  • Cromwell, Connecticut, United States
  • Norwich, Connecticut, United States
  • Hockessin, Delaware, United States
  • Fort Myers, Florida, United States
  • Jacksonville, Florida, United States
  • Lady Lake, Florida, United States
  • Miami, Florida, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Libertyville, Illinois, United States
  • Valparaiso, Indiana, United States
  • Overland Park, Kansas, United States
  • Prairie Village, Kansas, United States
  • Boston, Massachusetts, United States
  • Braintree, Massachusetts, United States
  • Pittsfield, Massachusetts, United States
  • St Louis, Missouri, United States
  • Cherry Hill, New Jersey, United States
  • Fresh Meadows, New York, United States
  • New York, New York, United States
  • Olean, New York, United States
  • Cincinnati, Ohio, United States
  • Columbus, Ohio, United States
  • Middleburg Heights, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Emmaus, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Reading, Pennsylvania, United States
  • North Charleston, South Carolina, United States
  • Nashville, Tennessee, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Midlothian, Virginia, United States
  • Waukesha, Wisconsin, United States
09

References and documents

Publications

  • Mahableshwarkar AR, Jacobsen PL, Serenko M, Chen Y. A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder. Hum Psychopharmacol. 2014 Jan;29(1):64-72. doi: 10.1002/hup.2371. PubMed 24424707 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Jan 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 4 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2008
First posted
Aug 8, 2008
Start
Jun 2008
Primary completionActual
Jan 2009
CompletionActual
Feb 2009
Results first posted
Dec 18, 2013
Last update
Dec 18, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00731120
Lead sponsor
Takeda
Collaborators
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Aug 8, 2008
Start date
Jun 2008
Primary completion
Jan 2009
Completion
Feb 2009
Results posted
Dec 18, 2013
Last update
Dec 18, 2013

Study contacts

Medical Director, Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion